Press Release

Successful start to fiscal year 2019/20 for Carl Zeiss Meditec with profitable growth

Both strategic business units achieve double-digit percentage increases in revenue

10 February 2020

Jena/Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec generated revenue of €369.7m in the first three months of fiscal year 2019/20, which corresponds to an increase of 14.2% (adjusted for currency effects: +12.7%) compared with the prior-year period (prior year: €323.6m). Both strategic business units achieved significant increases in revenue. Earnings before interest and taxes (EBIT) rose as a result of the increase in revenue, to €56.8m (prior year: €48.1m). The EBIT margin increased further, to 15.4% (prior year: 14.9%).


“We have made a successful start to the new fiscal year and can report encouraging growth in all business segments. Both our traditional equipment business and our consumables business made outstanding contributions to this,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Double-digit growth in both strategic business units

The strategic business unit (SBU) Ophthalmic Devices increased its revenue by 12.5 percent after the first three months of fiscal year 2019/20 (adjusted for currency effects: +11.1 percent), to €269.4m (prior year: €239.5m).
Revenue in the Microsurgery SBU grew by 19.1 percent (adjusted for currency effects: +17.4 percent), to €100.3m (prior year: €84.2m).

Balanced growth in all business regions

Revenue in the EMEA region grew by 7.0 percent (adjusted for currency effects: +6.9 percent), to €110.7m (prior year: €103.5m). The core markets Germany and France achieved good revenue growth.

The Americas region increased its revenue by 18.5 percent after the first three months of the current fiscal year (adjusted for currency effects: 15.5 percent), to €109.0m (prior year: €91.9m). High contributions to growth came from the USA, as well as positive impetus from Latin America.

The APAC region also achieved further growth of 16.9 percent (adjusted for currency effects: +15.5 percent), to €150.0m (prior year: €128.2m). Countries such as China and South Korea once again made the strongest contributions to growth. The Japanese market also recorded good demand.

The operating result (earnings before interest and taxes: EBIT) increased significantly in the first quarter of fiscal year 2019/20, reaching €56.8m (prior year: €48.1m). The EBIT margin increased from 14.9 percent to 15.4 percent. Adjusted for special effects, this resulted in an increase to 15.7 percent (prior year: 15.1%). The earnings pro share increased to € 0.43 (previous year: € 0.32).

“In fiscal year 2019/20, we anticipate revenue growth that is at least in line with our markets. In terms of the development of earnings, we expect to achieve an EBIT margin of between 17% and 19% in the current fiscal year” says Dr. Monz, confirming the outlook published in December 2019.

  • All figures in €m

    3 months 2019/20

    3 months 2018/19

    Change from prior year

    Change from prior year (adjusted for currency effects)

    Ophthalmic Devices

    269.4

    239.5

    +12.5%

    +11.1%

    Microsurgery

    100.3

    84.2

    +19.1%

    +17.4%

    Overall group

    369.7

    323.6

    +14.2%

    +12.7%

  • All figures in €m

    3 months 2019/20

    3 months 2018/19

    Change from prior year

    Change from prior year (adjusted for currency effects)

    EMEA

    110.7

    103.5

    +7.0%

    +6.9%

    Americas

    109.0

    91.9

    +18.5%

    +15.5%

    APAC

    150.0

    128.2

    +16.9%

    +15.5%

    Overall group

    369.7

    323.6

    +14.2%

    +12.7%

Press & Investor Relations Contact

Sebastian Frericks

Director Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

 


Share this article